DATROWAY approved in the U.S. as first TROP2 directed therapy for patients with previously treated...

MediLink announces YL201 granted Breakthrough Therapy Designation by FDA

Huadong Medicine’s FGFR2b target ADC innovative drug HDM2020 China IND was approved by the NMPA

Dong-A ST files IND for Phase 1 clinical trial of ADC candidate for cancer

Bio-Thera Solutions announce first patient dosed in Phase 3 clinical Trial for BAT8006, an Antibody...

Corbus Pharmaceuticals announces first patient dosed with its Nectin-4 targeting ADC CRB-701 in combination with...